Allogene Therapeutics, Inc. (ALLO) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 4.64M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $4.64M | (m) | (m) |
| 2025-12-31 | (m) | $0.00 | (m) | (m) |
| 2025-09-30 | (m) | $0.00 | (m) | (m) |
| 2025-06-30 | (m) | $0.00 | (m) | (m) |
| 2025-03-31 | (m) | $0.00 | (m) | (m) |
| 2024-12-31 | (m) | $22.00K | (m) | (m) |
| 2024-09-30 | (m) | $43.00K | (m) | (m) |
| 2024-06-30 | (m) | $65.00K | (m) | (m) |
| 2024-03-31 | (m) | $87.00K | (m) | (m) |
| 2023-12-31 | (m) | $95.00K | (m) | (m) |
| 2023-09-30 | (m) | $186.00K | (m) | (m) |
| 2023-06-30 | (m) | $192.00K | (m) | (m) |
| 2023-03-31 | (m) | $234.00K | (m) | (m) |
| 2022-12-31 | (m) | $243.00K | (m) | (m) |
| 2022-09-30 | (m) | $247.00K | (m) | (m) |
| 2022-06-30 | (m) | $247.00K | (m) | (m) |
| 2022-03-31 | (m) | $205.00K | (m) | (m) |
| 2021-12-31 | (m) | $38.49M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $0.00 | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |